Jump to ContentJump to Main Navigation

Biological Chemistry

Editor-in-Chief: Brüne, Bernhard

Editorial Board Member: Buchner, Johannes / Ludwig, Stephan / Sies, Helmut / Turk, Boris / Wittinghofer, Alfred

12 Issues per year


IMPACT FACTOR increased in 2014: 3.268
Rank 106 out of 289 in category Biochemistry & Molecular Biology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2014: 1.596
Source Normalized Impact per Paper (SNIP) 2014: 0.845
Impact per Publication (IPP) 2014: 2.992

VolumeIssuePage

Issues

Biochemical Characterization of the Catalytic Domain of Membrane-Type 4 Matrix Metalloproteinase

Hansjörg Kolkenbrock / Lutz Essers / Norbert Ulbrich / Horst Will

Citation Information: Biological Chemistry. Volume 380, Issue 9, Pages 1103–1108, ISSN (Print) 1431-6730, DOI: 10.1515/BC.1999.137, June 2005

Publication History

Published Online:
2005-06-01

Abstract

A C-terminal truncated form of membrane-type 4 matrix metalloproteinase (MT4-MMP; MMP 17), lacking the hemopexin-like and transmembrane domain, was expressed in Escherichia coli. The catalytic domain was produced by tryptic activation of the recombinant proenzyme and proved to be catalytically active towards the fluorogenic substrate for matrix metalloproteinases (7-methoxycoumarin-4-yl) acetyl-Pro- Leu-Gly-Leu(3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl)- Ala-Arg-NH2.

In contrast to the other three MT-MMPs (MT1-, MT2-, and MT3-MMP), the catalytic domain of MT4-MMP does not activate progelatinase A, nor does it hydrolyze one of the offered extracellular matrix (ECM) proteins, such as collagen types I, II, III, IV, and V, gelatin, fibronectin, laminin or decorin. TIMP-1, a poor inhibitor of MT1-, MT2- and MT3-MMP, suppresses MT4-MMP activity effectively. The progelatinase A/TIMP-2 complex that usually reacts like TIMP-2 also inhibits MT4-MMP. TIMP-2, a strong inhibitor of other MT-MMPS, inhibits MT4-MMP at low concentrations. With increasing TIMP-2 concentration, however, activity passes through a minimum and then increases until at high TIMP-2 concentration the activity is the same as in the absence of TIMP-2. TIMP-1 or the progelatinase A/TIMP-2 complex do not prevent reactivation of MT4-MMP catalytic domain at high TIMP-2 concentrations.

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[2]
William Roger English, Gloria Velasco, Jan Olaf Stracke, Vera Knäuper, and Gillian Murphy
FEBS Letters, 2001, Volume 491, Number 1-2, Page 137
[3]
Diego Sbardella, Giovanni Francesco Fasciglione, Magda Gioia, Chiara Ciaccio, Grazia Raffaella Tundo, Stefano Marini, and Massimo Coletta
Molecular Aspects of Medicine, 2012, Volume 33, Number 2, Page 119
[4]
Hajime Yamanaka, Ken-ichi Makino, Masayuki Takizawa, Hiroyuki Nakamura, Noboru Fujimoto, Hideshige Moriya, Ryoichi Nemori, Hiroshi Sato, Motoharu Seiki, and Yasunori Okada
Laboratory Investigation, 2000, Volume 80, Number 5, Page 677
[5]
Marie-Christine Gauthier, Christine Racine, Claudine Ferland, Nicolas Flamand, Jamila Chakir, Guy M. Tremblay, and Michel Laviolette
The International Journal of Biochemistry & Cell Biology, 2003, Volume 35, Number 12, Page 1667
[6]
Michelle A. Rudek, Jürgen Venitz, and William D. Figg
Pharmacotherapy, 2002, Volume 22, Number 6, Page 705
[8]
H. Smolian, A. Aurer, M. Sittinger, J. Zacher, J.-P. Bernimoulin, G.-R. Burmester, and H. Kolkenbrock
Biological Chemistry, 2001, Volume 382, Number 10
[9]
Hansjörg Kolkenbrock, Jürgen Zimmermann, Gerd-R. Burmester, and Norbert Ulbrich
Biological Chemistry, 2000, Volume 381, Number 1
[11]
Vincent Chabottaux, Stéphanie Ricaud, Laurent Host, Silvia Blacher, Alexandra Paye, Marc Thiry, Anikitos Garofalakis, Carine Pestourie, Karine Gombert, Françoise Bruyere, Daniel Lewandowsky, Bertrand Tavitian, Jean-Michel Foidart, Frédéric Duconge, and Agnès Noel
Journal of Cellular and Molecular Medicine, 2009, Volume 13, Number 9b, Page 4002
[12]
Asmaa B. Hamze, Shuo Wei, Harinath Bahudhanapati, Smitha Kota, K. Ravi Acharya, and Keith Brew
Protein Science, 2007, Volume 16, Number 9, Page 1905
[13]
Prediman K Shah, Douglas J Wilkin, Terence M Doherty, Hiroyasu Uzui, Tripathi B Rajavashisth, Kamlesh Asotra, and Duanqing Pei
Expert Opinion on Therapeutic Patents, 2002, Volume 12, Number 5, Page 665
[14]
Anjum Sohail, Qing Sun, Huiren Zhao, M. Margarida Bernardo, Jin-Ah Cho, and Rafael Fridman
Cancer and Metastasis Reviews, 2008, Volume 27, Number 2, Page 289
[15]
Joseph F. Porter, Shashi Sharma, Donna L. Wilson, Maya A. Kappil, Ronald P. Hart, and David T. Denhardt
Breast Cancer Research and Treatment, 2005, Volume 94, Number 2, Page 185

Comments (0)

Please log in or register to comment.